Stocktoria
ADAPTIN BIO, INC. APTN
OTC · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2026-03-17
ADAPTIN BIO, INC. financials (annual, from 10-K)
Bars are annual figures from 2023 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | $1.8M | $1.8M | — |
| Operating income | -$5.4M | -$2.6M | -$85,593 |
| Net income | -$5.2M | -$3.1M | -$85,593 |
| EPS (diluted) | $-0.66 | $-0.96 | $-0.02 |
| Operating cash flow | -$4.8M | -$649,283 | -$81,035 |
| Cash & equivalents | $459,174 | $34,085 | $380 |
| Total assets | $619,159 | $239,415 | $380 |
| Total liabilities | $2.1M | $4.3M | $113,277 |
| Shareholders' equity | -$1.5M | -$4.1M | -$977,559 |
Source: SEC EDGAR filings · CIK 0001938571 · US · as of 2025-12-31. facts plus Stocktoria's own computed scores — not investment advice.